Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.77 |
| ▸ | BRD3 | Q15059 | 14/20 | 0.60 |
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | HTR2C | P28335 | 2/20 | 0.54 |
| ▸ | CDC42 | P60953 | 1/20 | 0.47 |
| ▸ | RB1 | P06400 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5455600 | 1.00 | CYP2D6 (0.77) | CYP2D6KCNH2BRD3HTR2AHTR2C | |
| SCHEMBL4194153 | 0.88 | CYP2D6 (0.78) | CYP2D6KCNH2BRD3CDC42RB1 | |
| SCHEMBL4195673 | 0.88 | CYP2D6 (0.78) | CYP2D6KCNH2BRD3CDC42RB1 | |
| SCHEMBL4149725 | 0.88 | CYP2D6 (0.78) | CYP2D6KCNH2BRD3CDC42RB1 | |
| SCHEMBL4172408 | 0.88 | CYP2D6 (0.78) | CYP2D6KCNH2BRD3CDC42RB1 | |
| SCHEMBL4199294 | 0.88 | CYP2D6 (0.78) | CYP2D6KCNH2BRD3CDC42RB1 | |
| SCHEMBL5461901 | 0.88 | CYP2D6 (0.78) | CYP2D6KCNH2BRD3CDC42RB1 | |
| SCHEMBL20537339 | 0.88 | CYP2D6 (0.78) | CYP2D6KCNH2BRD3CDC42RB1 | |
| SCHEMBL20537338 | 0.88 | CYP2D6 (0.78) | CYP2D6KCNH2BRD3CDC42RB1 | |
| SCHEMBL4194377 | 0.88 | CYP2D6 (0.78) | CYP2D6KCNH2BRD3CDC42RB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
| EP-1678137-A1 | COMPOSITIONS AND METHODS FOR VIRAL INHIBITION | CHIRON CORPORATION (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005037791-A1 | COMPOSITIONS AND METHODS FOR VIRAL INHIBITION | CHIRON CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | MAVS, SARS1, ZC3HAV1 | CYP2D6 670/4885KCNH2 3684/4885BRD3 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.